Nasus Pharma LtdNSRX
Price$3.81

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $1.2BTTM through 31 Dec 2025
Net Income -$5.9MTTM through 31 Dec 2025
Free Cash Flow -$4.9MTTM through 31 Dec 2025

Margins

Current
Gross Margin0.0%
Operating Margin-0.4%
Net Margin-0.5%

Returns

-209.7%ROE
-107.2%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio2.24x
Net Debt-$4.3Mnet cash position
Cash & Equivalents$1.2M

Quality Metrics

Altman Z-Score250.25
Piotroski F-Score3 / 9
FCF Margin-0.4%

Multi-Year Trend

Revenue
'25
FY2025: $1.2B
Diluted EPS-$0.72TTM
'23'24'25
FY2025: $-0.73

Dividend

No dividend

Capital Allocation

R&D Spend$2.2M
Capex Intensity1,133.6%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.